William Blair analyst Sarah Schram has reiterated their bullish stance on DNLI stock, giving a Buy rating yesterday.
Sarah Schram’s rating is based on the potential of Denali Therapeutics’ lead asset, tivi, which is on track for an accelerated approval BLA filing in early 2025 to treat Hunter syndrome. Despite the recent disappointing results from the DNL343 program, the focus remains on tivi, which is considered a best-in-class treatment option due to its promising biomarker and clinical outcomes data.
Additionally, Denali’s unique transport vehicle (TV) platform, which aims to deliver drugs effectively to the brain, continues to show potential. The company plans to advance one to two assets into the clinic annually over the next three years, further supporting its growth prospects. Despite a 20% decline in share value year-to-date, the market appears to undervalue Denali’s programs and platform, making it an attractive investment opportunity.
In another report released yesterday, B.Riley Financial also maintained a Buy rating on the stock with a $35.00 price target.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DNLI in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com